AJP - GI Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol 294: G1411-G1420, 2008. First published April 24, 2008; doi:10.1152/ajpgi.00181.2007
0193-1857/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/6/G1411    most recent
00181.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Freudenberg, F.
Right arrow Articles by Carey, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freudenberg, F.
Right arrow Articles by Carey, M. C.

LIVER AND BILIARY TRACT

Pathophysiological basis of liver disease in cystic fibrosis employing a {Delta}F508 mouse model

Folke Freudenberg,1,2 Annemarie L. Broderick,1,2,3 Bian B. Yu,2 Monika R. Leonard,2 Jonathan N. Glickman,4 and Martin C. Carey1,2

1Department of Medicine, Harvard Medical School and Harvard Digestive Diseases Center, Boston; 2Department of Medicine, Gastroenterology Division, Brigham and Women's Hospital, Boston; 3Combined Program of Gastroenterology and Nutrition, Children's Hospital, Boston; and 4Pathology Department, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts

Submitted 25 April 2007 ; accepted in final form 20 April 2008

The molecular pathogenesis of cystic fibrosis (CF) liver disease is unknown. This study investigates its earliest pathophysiological manifestations employing a mouse model carrying {Delta}F508, the commonest human CF mutation. We hypothesized that, if increased bile salt spillage into the colon occurs as in the human disease, then this should lead to a hydrophobic bile salt profile and to "hyperbilirubinbilia" because of induced enterohepatic cycling of unconjugated bilirubin. Hyperbilirubinbilia may then lead to an increased bile salt-to-phospholipid ratio in bile and, following hydrolysis, precipitation of divalent metal salts of unconjugated bilirubin. We document in CF mice elevated fecal bile acid excretion and biliary secretion of more hydrophobic bile salts compared with control wild-type mice. Biliary secretion rates of bilirubin monoglucuronosides, bile salts, phospholipids, and cholesterol are increased significantly with an augmented bile salt-to-phospholipid ratio. Quantitative histopathology of CF livers displays mild early cholangiopathy in {approx}53% of mice and multifocal divalent metal salt deposition in cholangiocytes. We conclude that increased fecal bile acid loss leads to more hydrophobic bile salts in hepatic bile and to hyperbilirubinbilia, a major contributor in augmenting the bile salt-to-phospholipid ratio and endogenous β-glucuronidase hydrolysis of bilirubin glucuronosides. The confluence of these perturbations damages intrahepatic bile ducts and facilitates entrance of unconjugated bilirubin into cholangiocytes. This study of the earliest stages of CF liver disease provides a framework for investigating the molecular pathophysiology of more advanced disease in murine models and in humans with CF.

cystic fibrosis transmembrane conductance regulator; gallstones; enterohepatic cycling; bilirubin; metal salts



Address for reprint requests and other correspondence: M. C. Carey, Brigham and Women's Hosp., Gastroenterology Div., 75 Francis St., Boston, MA 02115 (e-mail: mccarey{at}rics.bwh.harvard.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.